Ultrashort cephalic paroxysms are well known. In the parish of Vågå, Norway, 35.2% of the 18-65-year-old subjects (n = 1779) were recently found to have such jabs. In the present work, a search has been made for extracephalic 'jabs'. A questionnaire was in its entirety administered by the same investigator (O.S.) in a 'semistructured' way. Facial jabs were present in three women, and in one of them the pain spread to the head. Four subjects had jabs occurring at random throughout the body, also including the cephalic area. Pure nuchal jabs were present in 12 subjects, 10 of whom were males. This sex preponderance difference differs significantly from that in jabs in general (with 40.2% males). The characteristics of the extracephalic jabs, i.e. the duration and temporal pattern, do not seem to differentiate them essentially from jabs in general. The subjects were not asked specific questions regarding extracranial jabs. Most of the affected individuals gave information spontaneously about their jabs. For these reasons, this study is not a proper prevalence study. It does show, however, that extracranial jabs exist, and it gives some indications as to their frequency.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1046/j.1468-2982.2003.00473.x | DOI Listing |
Heliyon
December 2024
Research Laboratory for Biomechanics and Implant Technology, Department of Orthopaedics, Rostock University Medical Center, Rostock, Germany.
Subject-specific finite element (FE) modeling of the mandible bone has recently gained attention for its higher accuracy. A critical modeling factor is including personalized material properties from medical images especially when bone quality has to be respected. However, there is no consensus on the material model for the mandible that realistically estimates the Young's modulus of the bone.
View Article and Find Full Text PDFInt J Eat Disord
December 2024
Flinders University Institute for Mental Health and Wellbeing, Flinders University, South Australia, Australia.
BMC Cancer
December 2024
CeMOS, Mannheim University of Applied Sciences, 68163, Mannheim, Germany.
Background: The growth and drug response of tumors are influenced by their stromal composition, both in vivo and 3D-cell culture models. Cell-type inherent features as well as mutual relationships between the different cell types in a tumor might affect drug susceptibility of the tumor as a whole and/or of its cell populations. However, a lack of single-cell procedures with sufficient detail has hampered the automated observation of cell-type-specific effects in three-dimensional stroma-tumor cell co-cultures.
View Article and Find Full Text PDFBirth Defects Res
December 2024
Birth Defects Registry, New York State Department of Health, Albany, New York, USA.
Background: Previous studies of maternal alcohol consumption and craniosynostosis have reported null or inverse associations. We updated a previous analysis of National Birth Defects Prevention Study (NBDPS) data to further examine associations between maternal alcohol consumption and craniosynostosis.
Methods: NBDPS was a multi-site, population-based case-control study.
Ophthalmology
November 2024
Center for Clinical Trials and Evidence Synthesis, Departments of Epidemiology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA; Department of Ophthalmology, The Wilmer Eye Institute, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Purpose: Evaluation of longer-term effectiveness of three intravitreal therapies (methotrexate, ranibizumab, or dexamethasone implant) for participants enrolled in the randomized comparative effectiveness trial the Macular Edema Ranibizumab versus Intravitreal anti-inflammatory Therapy (MERIT) Trial followed for24 weeks.
Design: Multicenter randomized controlled clinical trial with masked evaluation of retinal thickness and visual acuity.
Participants: Patients with persistent or recurrent uveitic macular edema.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!